A5090898735- Antibiotic Resistance in Bacteria
- Antibiotics Pharmacokinetics and Efficacy
- Pneumonia and Respiratory Infections
- Antibiotic Use and Resistance
- Vibrio bacteria research studies
- Bacteriophages and microbial interactions
- Tuberculosis Research and Epidemiology
- Pharmacogenetics and Drug Metabolism
- Antimicrobial Resistance in Staphylococcus
- Epilepsy research and treatment
- HIV/AIDS drug development and treatment
- Infections and bacterial resistance
- Microbial infections and disease research
- Computational Drug Discovery Methods
- HIV Research and Treatment
- Phenothiazines and Benzothiazines Synthesis and Activities
- Bacterial Identification and Susceptibility Testing
- Statistical Methods in Clinical Trials
- Cancer therapeutics and mechanisms
- Inhalation and Respiratory Drug Delivery
- Bacterial Infections and Vaccines
- Renal Transplantation Outcomes and Treatments
- Erythropoietin and Anemia Treatment
- Evolution and Genetic Dynamics
- Pneumocystis jirovecii pneumonia detection and treatment
University of North Carolina at Chapel Hill
2017-2025
University of Southern California
2024-2025
Marymount California University
2025
University at Buffalo, State University of New York
2009-2022
University of Florida
2019
Columbus Oncology and Hematology Associates
2019
Princess Anne Hospital
2011
University Hospital Lewisham
2000
National Institutes of Health
1998
Abstract Objectives Colistin is an ‘old’ drug, which being increasingly utilized due to limited therapeutic options. However, resistance emergence during monotherapy concerning. Here, our objective was optimize colistin combinations against Pseudomonas aeruginosa by profiling the time course of synergistic killing and prevention resistance. Methods Hollow-fibre infection models over 10 days simulated clinically relevant dosage regimens doripenem two heteroresistant P. strains (MIC 1 mg/L)...
SARS-CoV-2 utilizes the IMPα/β1 heterodimer to enter host cell nuclei after gaining cellular access through ACE2 receptor. Ivermectin has shown antiviral activity by inhibiting formation of importin-α (IMPα) and IMPβ1 subunits as well dissociating in vitro efficacy against SARS-CoV-2. Plasma lung ivermectin concentrations vs. time profiles cattle were used determine apparent plasma tissue partition coefficient ivermectin. This coefficient, together with a simulated geometric mean profile...
ABSTRACT Foremost in the design of new β-lactamase inhibitors (BLIs) are boronic acid transition state (BATSIs). Two highly potent BATSIs being developed S02030 and MB076 strategically designed to be active against cephalosporinases carbapenemases, especially KPC. When combined with cefepime, demonstrated antimicrobial activity laboratory clinical strains Enterobacterales expressing a variety class A C β-lactamases, including bla KPC-2 KPC-3 . Static time-kill assays revealed bactericidal...
Abstract Background Stenotrophomonas maltophilia (Sma) is an increasingly important opportunistic bacterial pathogen that commonly causes bloodstream infection (BSI) or pneumonia. Sma intrinsically resistant to most antibiotics and may acquire additional resistance. Despite its significant clinical impact, remarkably understudied. Consequently, critical gaps persist in our understanding of Sma’s genomic microbiological characteristics, which impact treatment outcomes. Herein, we...
Abstract Background Pseudomonas aeruginosa (Pae) is a significant pathogen causing up to 10% of hospital-acquired infections. Contributing Pae’s multidrug-resistant (MDR) phenotype the inducible Pseudomonas-derived cephalosporinase (PDC), low permeability outer membrane, multiple efflux systems, and loss porins that yield resistant phenotypes. e.g. OprD yields resistance imipenem. Thus, design novel antibiotics or combination therapies do not induce expression blaPDC, are stable PDC...
Administering polymyxin antibiotics in a traditional fashion may be ineffective against Gram-negative ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens. Here, we explored increasing the dose intensity of B two strains baumannii hollow-fiber infection model. The following dosage regimens were simulated for (t1/2 = 8 h): non-loading (1.43 mg/kg body weight every 12 h [q12h]), loading...
The pharmacodynamics of polymyxin/carbapenem combinations against carbapenem-resistant Acinetobacter baumannii (CRAB) are largely unknown. Our objective was to determine whether intensified meropenem regimens in combination with polymyxin B enhance killing and resistance suppression CRAB.Time-kill experiments for were conducted three B-susceptible (MIC = 0.5 mg/L) CRAB strains varying MICs (ATCC 19606, N16870 03-149-1; MIC 4, 16 64 mg/L, respectively) at 108 cfu/mL. A hollow-fibre infection...
Polymyxins have resurged as the last-resort antibiotics against multidrug-resistant Acinetobacter baumannii. As reports of polymyxin resistance in A. baumannii with monotherapy become increasingly common, combination therapy is usually only remaining treatment option. A novel and effective strategy to combine polymyxins non-antibiotic drugs. This study aimed investigate, using untargeted metabolomics, mechanisms antibacterial killing synergy B a synthetic cannabidiol ATCC 19606. The panel...
Polymyxin B is being increasingly utilized as a last resort against resistant Gram-negative bacteria. We examined the pharmacodynamics of novel dosing strategies for polymyxin combinations to maximize efficacy and minimize emergence resistance drug exposure Acinetobacter baumannii. The together with doripenem were evaluated in time–kill experiments over 48 h 108 cfu/mL two polymyxin-heteroresistant A. baumannii isolates (ATCC 19606 N16870). Pharmacokinetic/pharmacodynamic relationships...
ABSTRACT Safe and effective therapies are urgently needed to treat polymyxin-resistant KPC-producing Klebsiella pneumoniae infections suppress the emergence of resistance. We investigated pharmacodynamics polymyxin B, rifampin, meropenem alone as B-based double triple combinations against K. isolates. The rates extents killing with B (1 128 mg/liter), rifampin (2 16 (10 120 mg/liter) were evaluated B-susceptible (PB s ) B-resistant r clinical isolates using 48-h static time-kill studies....
Aims Several clinical trials have confirmed the therapeutic benefit of imipenem for treatment lung infections. There is however no knowledge penetration into epithelial lining fluid (ELF), site action relevant Furthermore, although plasma pharmacokinetics (PK) has been widely studied, most studies based on selected patient groups. The aim this analysis was to characterize PK across populations and quantify ELF penetration. Methods A population model developed using data obtained from healthy...